⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
COYA News
Coya Therapeutics, Inc. Common Stock
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy
businesswire.com
COYA
Form 8-K
sec.gov
COYA
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results
businesswire.com
COYA
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
businesswire.com
COYA
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
businesswire.com
COYA
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
businesswire.com
COYA
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
businesswire.com
COYA
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
businesswire.com
COYA
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman
businesswire.com
COYA
AVIR
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
businesswire.com
COYA